Session Information
Date: Monday, October 8, 2018
Session Title: Parkinson's Disease: Pathophysiology
Session Time: 1:15pm-2:45pm
Location: Hall 3FG
Objective: Alpha-synuclein (α-syn) plays a very important role in pathogenesis of Parkinson’s disease (PD). There are enough evidence of neuroinflammation in the brain tissue of many neurodegenertive diseases, including PD. Many researchers found lymphocytes and macrophages infiltration in basal ganglia of the brain samples of patients died from PD complications. On the same time, systematical study of α-syn in the brain, serum and CSF of these patient still not performed.
Background: Under our observations were 56 PD patients, 39 men and 17 women, ages from 44 to 83 years old. Control group comprised from 124 healthy donors/ Also we used paraffin slices of cerebellum, brain stem and basal ganglia from patients died from PD complications.
Methods: We produced an enzyme-linked immunosorbent assay (ELISA) for measuring α-syn AAB (IgG) in the serum and CSF of PD patients. Also immunohistochemical study of the brains of 4 patients died from PD. We used antibodies marked by fluorescein-isotiocianate (FITC). Control slices of the brain tissue were taken from person died from PD and from non-neurological causes.
Results: Anti α-syn AAB were increased in 86 percent PD patients, both men -89 per cent and women – 74 per cent) Confocal luminescence was revealed fluorescence in substantia nigra, globus pallidum and locus cereleum in the brain histological samples received from dead PD patients. The histological brain samples from dead patients without any neurological diseases did not revealed any immunofluorescence in basal ganglia or any other brain region.
Conclusions: The studies of immune response in neurodegenerative disorders is a new part of pathogenetic approach to this problem. Antibodies to α-syn probably play an important role in clinical picture and complications of PD.
References: Elevated Serum α-Synuclein Autoantibodies in Patients with Parkinson’s Disease Relative to Alzheimer’s Disease and Controls. Shalash A, Salama M, Makar M, Roushdy T1, Elrassas H, Mohamed W, El-Balkimy M, Abou Donia M. Front Neurol. 2017 Dec 22;8:720. doi: 10.3389/fneur.2017.00720. eCollection 2017.
To cite this abstract in AMA style:
D. Labunskiy. Antibodies to alpha-Synuclein in Parkinson disease [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/antibodies-to-alpha-synuclein-in-parkinson-disease/. Accessed December 11, 2024.« Back to 2018 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/antibodies-to-alpha-synuclein-in-parkinson-disease/